Company

Bank

Analyst

Coverage

Opinion

Wk chg

8/16 cls

Amarin Corp. plc (NASDAQ:AMRN)

H.C. Wainwright

Andrew Fein

Upgrade

Buy (from neutral)

11%

$6

Fein also raised his target to $10 from $6 ahead of an Oct. 16 FDA advisory committee meeting to discuss an sNDA for Vascepa icosapent ethyl to expand the drug's label to include treatment of adults with high triglycerides with mixed dyslipidemia. Vascepa is approved to treat adult patients with severe hypertriglyceridemia. The PDUFA date is Dec. 20. Fein believes Amarin stock has been "punished disproportionately" in the last eight months due in part to disappointment following high expectations of a deal for Vascepa, a July follow-on in which Amarin raised $121.5M and skepticism about drug launches in general. He thinks a positive panel recommendation and FDA approval are likely.